Core Insights - Haleon plc, a leading global consumer company specializing in everyday health, has partnered with Salesforce to enhance engagement with pharmacies and healthcare professionals globally [1] - The collaboration will utilize Salesforce Life Sciences Cloud for Customer Engagement, Data Cloud, and Agentforce to support Haleon's global sales force of 4,500 [1] Company Overview - Haleon plc focuses on consumer health products and aims to improve its operational efficiency through advanced technology [1] - Salesforce, recognized as the world's 1 AI CRM, will provide the necessary tools to facilitate better customer interactions for Haleon [1] Technology Utilization - The integration of Salesforce's AI-powered solutions is expected to drive more effective engagement strategies within Haleon's sales operations [1] - The specific tools being implemented include Salesforce Life Sciences Cloud, which is tailored for the life sciences sector, enhancing customer engagement capabilities [1]

Core Insights - Emergen-C Junior Crystals are designed to make vitamin intake enjoyable for children, featuring a fun fizz and natural fruit flavors, eliminating the need for water [1][2][3] - Each packet contains 250 mg of Vitamin C, along with Zinc, B Vitamins, and Manganese, aimed at supporting children's immune systems and overall health [2][3] - The product is now available in Canada and is marketed as a convenient option for busy families, suitable for lunchboxes and on-the-go use [2][3] Company Overview - Haleon is a global leader in consumer health, focusing on delivering better everyday health with a human touch [4] - The company's product portfolio includes five major categories: Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements (VMS) [4] - Haleon's established brands, such as Advil, Sensodyne, and Centrum, are built on trusted science and innovation [4]

Guidance Adjustment - The company has lowered its full-year sales guidance from 4% to 3.5%, indicating a cautious outlook for the remainder of the year [1] - Despite the reduction, the company still anticipates a step-up in sales during the second half of the year, suggesting confidence in achieving at least the 3.5% target [1] Profit Guidance - The company has increased its profit guidance to high single digits on an organic basis, driven by a strong productivity program [2] - This adjustment reflects a positive outlook on profitability, even as sales growth expectations have been tempered [2]

Financial Data and Key Metrics Changes - The company revised its sales growth guidance to around 3.5%, while increasing profit guidance to high single digits on an organic basis, driven by a strong productivity program [4][5] - In the U.S., consumption growth was reported at 3.2% at the halfway point of the year, with a slight increase of approximately 0.5% in Q3, contrasting with a market decline of about 0.5% [4][5] Business Line Data and Key Metrics Changes - The company experienced mid-single-digit growth in EMEA, LATAM, and Asia-Pacific regions, with expectations for acceleration in these areas [6] - The oral health segment continued to perform well, with growth in the 3% range, particularly in therapeutic oral health, which is outpacing overall market growth [15][34] Market Data and Key Metrics Changes - The U.S. market is facing muted overall growth and continued inventory pressure, prompting the company to proactively manage inventory with retailers [5][12] - The company noted that the cold and flu season significantly impacted consumption dynamics, with a high season in Q1 followed by a lower allergy season in Q2 [14] Company Strategy and Development Direction - The company is focused on reaching a billion more consumers, particularly in emerging markets, targeting low-income consumers with tailored product launches [10] - There is a strong emphasis on innovation and premiumization in the oral health category, with new product launches and clinical claims expected to drive growth [34][36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the revised sales growth target of around 3.5%, despite challenges in the U.S. market [6][62] - The company is optimistic about the potential for growth in the U.S. and emerging markets, with plans to stabilize and improve market share in key categories [25][30] Other Important Information - The company is implementing a productivity program aimed at achieving £800 million in savings by 2030, with expectations of improving gross margins by 50 to 80 basis points annually [50][53] - The recent buyout of the joint venture partner in China is expected to unlock significant operational efficiencies and market potential [43][44] Q&A Session Summary Question: What is the assumption on destocking in the U.S. for the second half? - Management indicated good visibility on inventory levels with top customers and expects continued inventory reduction without significant swings higher [12][13] Question: How is the company executing with growing retailers like Amazon and Walmart? - Management confirmed strong partnerships with major retailers and emphasized the importance of adapting to channel shifts while maintaining consumer access [21][22] Question: What is the outlook for the BMS category in the U.S.? - Management acknowledged challenges in the U.S. BMS market but remains optimistic about new science-backed claims and product innovations driving future growth [28][30] Question: How confident is the company in achieving the 4% to 6% growth target by 2026? - Management expressed confidence in the medium-term guidance, citing a robust strategic planning process and expected improvements in the U.S. market [60][61]

Financial Data and Key Metrics Changes - The company has adjusted its sales growth guidance to around 3.5%, while profit guidance has been raised to high single digits on an organic basis, driven by a strong productivity program [4][5][6] - In the first half of the year, the company achieved a growth rate of 3.2% [4] - Gross margin increased by 160 basis points in the first half of the year [55] Business Line Data and Key Metrics Changes - The U.S. market showed a slight decline, with consumption up by approximately half a point in Q3, while the overall market was down by half a point [4][5] - The company experienced mid-single-digit growth in EMEA, LATAM, and Asia-Pacific regions, with expectations for acceleration in these areas [6] - Oral health performance continued to grow, with a consistent growth rate around 3% [17] Market Data and Key Metrics Changes - The U.S. market faced muted overall growth and continued inventory pressure, leading to a cautious outlook for the remainder of the year [5][6] - The company noted that the cold and flu season significantly impacted consumption dynamics, with a high season in Q1 followed by a lower allergy season in Q2 [15][16] Company Strategy and Development Direction - The company aims to reach a billion more consumers, particularly focusing on low-income consumers in emerging markets [10] - There is a strong emphasis on managing inventory proactively with retailers to avoid out-of-stock situations [5][13] - The company is optimistic about the potential of its brands in emerging markets, particularly in India and China, where it has launched products tailored for low-income consumers [33][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the 3.5% growth target, despite challenges in the U.S. market [6][63] - The company is focused on maximizing portfolio performance and improving market share, particularly in oral health and therapeutic categories [26][27] - Management acknowledged the cyclical nature of the market and expressed optimism about returning to growth in the U.S. [63] Other Important Information - The company is implementing a productivity program expected to deliver £800 million in savings by 2030, with a target of 50 to 80 basis points of gross margin improvement annually [52][55] - The company is focused on capital allocation towards automation and building additional plants in strategic locations [60][61] Q&A Session Summary Question: What is the company's outlook on cash flow and working capital? - Management acknowledged the importance of cash flow and indicated that improvements in inventory reduction and working capital could fund capital investments [69][79] Question: How is the company addressing the challenges in the U.S. market? - Management noted that the U.S. market has been challenging but expressed confidence in the potential for recovery and growth [63][80] Question: What is the vision for the new therapeutic skin health category? - Management indicated that the decision to break out therapeutic skin health as a new category was strategic and aimed at capturing growth opportunities [74]

Financial Data and Key Metrics Changes - The company reported a gross margin improvement of 160 basis points, contributing to strong cash flow and organic profit growth [7][19] - A&P (Advertising and Promotion) spending increased by 6.8% to 20.8% in the first half of the year, reflecting a strategic focus on growth drivers [19][21] - The company expects high single-digit operating profit growth for the year, driven by gross margin opportunities [55][78] Business Line Data and Key Metrics Changes - North America experienced a nearly 2% organic sales growth decline, attributed to a challenging consumer environment and inventory pressures [4][8] - Strong growth and market share gains were noted in oral health and digestive health brands, while pain relief and VMS (Vitamins, Minerals, and Supplements) showed mixed performance [11][12] - Centrum faced challenges in the U.S. market, with declines despite strong growth outside the U.S. [13][14] Market Data and Key Metrics Changes - EMEA, Latin America, and APAC markets performed well, with organic sales growth within the medium-term guidance of 4% to 6% [4][8] - Volume growth in EMEALATAM accelerated from 0.5% in Q1 to 1.6% in Q2, while Asia Pacific saw an increase from 3.3% to 3.9% [47][50] - The U.S. market showed a decline in volume, down 1.8% in Q2, impacting overall performance [48][49] Company Strategy and Development Direction - The company remains committed to its medium-term guidance of 4% to 6% growth, despite current challenges in the U.S. market [45][50] - Strategic investments are focused on supply chain productivity, innovation, and expanding access to lower-income consumers [18][39] - The company plans to continue its innovation-led premiumization strategy while addressing core business challenges [40][55] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a challenging consumer environment in North America, with expectations of continued inventory pressures [8][16] - The company is optimistic about returning to growth in 2026, supported by new leadership and strategic initiatives [49][50] - Management expressed confidence in the resilience of the European market, particularly in oral health [52][53] Other Important Information - The nicotine replacement therapy business is a significant but challenging category, with a complex ownership structure impacting innovation [73][75] - The company is actively managing inventory levels with retailers to navigate the current economic environment [15][28] Q&A Session Summary Question: North America's performance and future growth expectations - Management noted that North America faced a nearly 2% decline in organic sales growth due to a challenging consumer environment and inventory pressures, with expectations for gradual recovery [4][8][16] Question: A&P spending and areas of reinvestment - A&P spending increased significantly, with a focus on driving growth through innovation and reaching lower-income consumers [19][21] Question: Share performance and competitive pressures - The decline in the percentage of business gaining or maintaining share was attributed to challenges with key brands like Advil and Centrum, with plans in place to stabilize performance [30][32] Question: Retailer environment and channel dynamics - Management discussed the impact of retailer destocking and channel shifts, particularly in the U.S. market, and emphasized the need to adapt to these changes [28][86] Question: Outlook for specific product categories - Management provided insights on the performance of Advil, Smoker's Health, and Centrum, highlighting ongoing challenges and upcoming innovations [60][66][68]

Financial Data and Key Metrics Changes - The company reported a decline in organic sales growth in North America of nearly 2% in Q2, contrasting with growth in EMEA, LatAm, and APAC, which were within the medium-term guidance of 4% to 6% [3][5][14] - Gross margin improved by 160 basis points, contributing to strong cash flow and organic profit growth [5][15] - A&P (Advertising and Promotion) spending increased by 6.8% to 20.8% in the first half of the year, reflecting a focus on growth drivers [16][19] Business Line Data and Key Metrics Changes - In North America, consumption grew slightly ahead of the market, with a 0.5% increase compared to a market decline of 0.5% [9][10] - Oral health and digestive health brands showed strong growth, with market share gains in brands like Tons and Benefiber [9][10] - Centrum experienced mid-single-digit growth outside the US but saw declines in the US, while Emergency brand continued to perform well [11][12] Market Data and Key Metrics Changes - The US market is facing challenges with low consumer confidence and inventory pressures, impacting overall performance [6][8][14] - EMEA and APAC regions showed positive trends, with volume growth accelerating in Q2 [47][51] - Central Europe reported high single-digit growth, while Western Europe experienced mid-single-digit growth, driven by strong performance in oral health [53][54] Company Strategy and Development Direction - The company remains committed to its medium-term guidance of 4% to 6% organic sales growth despite current challenges in the US market [49][56] - Focus on innovation and premiumization, particularly in key markets like India and Brazil, is part of the strategic plan [39][40] - The company aims to close the incidence treatment gap and expand reach to lower-income consumers while maintaining investment in A&P and R&D [16][19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenging consumer environment in the US, with expectations of continued inventory pressure and no significant improvement anticipated in the near term [14][22] - Confidence in the medium-term outlook remains strong, with expectations for improved performance in 2026 [49][56] - The company is actively managing its portfolio and focusing on driving market growth despite external challenges [36][41] Other Important Information - The nicotine replacement therapy (NRT) business is a significant part of the portfolio, with a complex ownership structure affecting innovation and growth [73][75] - The company expects a high single-digit growth in operating profit, supported by gross margin improvements and effective cost control [77][78] Q&A Session Summary Question: North America's performance and future growth expectations - Management noted that North America faced challenges due to a difficult consumer environment and inventory pressures, with expectations for a gradual return to growth [3][22][25] Question: A&P spending and areas of reinvestment - A&P spending increased significantly, with a focus on driving growth in key markets and improving ROI [16][19] Question: Share performance and competitive pressures - The decline in the percentage of business gaining or maintaining share was attributed to challenges with brands like Advil and Centrum, with plans in place to stabilize performance [28][30] Question: Impact of nicotine replacement therapy on growth - The NRT business had a significant impact on overall growth, with expectations for less decline in the second half of the year [76][80] Question: Channel shifts and inventory management - Management discussed the impact of channel shifts, particularly towards e-commerce, and the need for effective inventory management across channels [86][90]

2025 Half year results July 2025 Disclaimer This presentation contains certain statements that are, or may be deemed to be, "forward-looking statements" (including for purposes of the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements give Haleon's current expectations and projections about future events, including strategic initiatives and future financial condition ...

Core Viewpoint - HLN's MSCI ESG rating has been upgraded from A to AA as of July 30, 2025, indicating improved performance in environmental, social, and governance factors [1] Group 1 - The upgrade reflects HLN's enhanced commitment to ESG practices [1] - The new rating positions HLN more favorably in the market, potentially attracting more investors focused on sustainability [1]

Group 1 - Haleon has completed the acquisition of the remaining 12% stake in China-SK Pharmaceutical Co., Ltd, marking the end of a nearly 40-year joint venture with a total transaction value of 1.623 billion yuan [1][2] - The joint venture, established in 1984, was set to last until June 30, 2025, but the lifting of foreign ownership restrictions in China allowed Haleon to take full control [2] - The separation signifies a shift in the business landscape, as joint ventures have become less adaptable to the evolving strategies of multinational pharmaceutical companies [1][3] Group 2 - China-SK has been a significant player in the Chinese pharmaceutical market, focusing on pain management, respiratory health, skin health, and digestive health, with well-known brands such as Fenbid and New Contac [3][4] - Following the acquisition, Haleon plans to enhance its development strategy for China-SK, leveraging its strong brand portfolio and established sales network while investing in product lines based on consumer demand [4][5] - China is a key market for Haleon, driving global growth and enhancing brand competitiveness, with the acquisition seen as a major milestone in deepening its commitment to the Chinese market [5]